Risperdal is an atypical antipsychotic drug generally prescribed by doctors for patients suffering from symptoms of schizophrenia and bipolar disorder (also called manic depression). It is an atypical antipsychotic drug in two ways: first, its chemical composition is not related to earlier antipsychotic drugs and second, aside from affecting dopamine, Risperdal also affect serotonin levels (which are both influential in balancing mental wellbeing).
One advantage of taking Risperdal is that is has lower possibilities of causing side effects similar to Parkinson’s disease. Because these symptoms can cause severe issues for many patients, many often tend to discontinue treatments for their schizophrenia, which could eventually cause the condition to worsen. Additionally, most people have positive response with Risperdal compared to older antipsychotic drugs. Recent studies have shown that Risperdal (and its injectible version Risperdal Consta) have given significant improvements of symptoms for patients suffering from early symptoms of psychosis. Patients have also reported positive effects on their social and work functioning.
Risperdal is prescribed to both adults and children, but it is not a cure to these mental conditions. Rather, Risperdal helps in alleviating and managing the symptoms, along with prevention of possible relapses of the condition. Although Risperdal is also used for many “off-label” conditions, patients should understand that the drug Risperdal is not approved by the FDA (Food and Drug Administration) for these conditions. Taking Risperdal can increase your chances of severe side effects and health complications. As a matter of fact, as recent as November 4, 2013, manufacturers of Risperdal have settled a class action lawsuit put against them. This is in connection to health fraud, incorrect branding and marketing, and poor information about possible side effects. Many claimants have reportedly suffered from gynecomastia, a condition where men develop enlarged breasts with milk production. Johnson & Johnson, manufacturer of the Risperdal, has paid $ 2.2 million in settlement.Read More